Company / EPS (Diluted)
Bristol Myers Squibb EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$3.86
FY2025
5-year range
-$3.99 / $3.86
FY2021-FY2025
Trend
+30.8%
vs FY2024
Sector context
#15 of 204
Health Care
What the data says
Among 204 Health Care companies, Bristol Myers Squibb is in the top 7% for eps (diluted). EPS (Diluted) has fluctuated over the past 10 years, ranging from $-3.99 in FY2022 to $3.86 in FY2025.
Based on SEC 10-K filings.
3.86 in FY2025 with a 5-year CAGR of +5.1%. Top quartile in the Health Care sector.
Improved from $3.12 to $3.86 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +5.1%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 204This company $3.86 Sector average -$0.89
▼
+531.3% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 30.8% year-over-year.
- Ranks #15 out of 204 companies in the Health Care sector.
- Lowest eps (diluted) in the period was in FY2022.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.85 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 32.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.86 | +30.8% |
| FY2024 | $2.95 | -5.4% |
| FY2023 | $3.12 | +178.2% |
| FY2022 | -$3.99 | -298.5% |
| FY2021 | $2.01 | -33.2% |
| FY2020 | $3.01 | +393.4% |
| FY2019 | $0.61 | -77.0% |
| FY2018 | $2.65 | +184.9% |
| FY2017 | $0.93 | -22.5% |
| FY2016 | $1.20 | -22.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026